How to Lose Visceral Fat During Menopause

How to get rid of visceral fat in menopause is a question many women face as hormonal changes cause fat to shift from the hips and thighs towards the abdomen. This deep abdominal fat, known as visceral fat, carries greater health risks than ordinary body fat and can be frustratingly resistant to the approaches that worked earlier in life. Understanding why this happens, how visceral fat differs from subcutaneous fat, and which diet, exercise and medical options have genuine evidence behind them can help women make informed decisions and set realistic expectations during the menopause transition.

Why do women gain belly fat during menopause?

Falling oestrogen levels during menopause cause the body to redistribute fat from the hips and thighs to the abdomen, compounded by reduced insulin sensitivity, rising cortisol, sleep disruption and age-related muscle loss.

Women gain belly fat during menopause primarily because falling oestrogen levels cause the body to redistribute fat away from the hips and thighs and towards the abdomen. Oestrogen plays an active role in regulating where the body stores energy, and as ovarian production declines during perimenopause and menopause, adipose tissue increasingly accumulates around the internal organs rather than subcutaneously. Ageing and reduced physical activity also contribute, and the overall picture is one of several overlapping factors rather than a single cause.

Several interconnected mechanisms drive this change. Declining oestrogen is associated with reduced insulin sensitivity, making it easier for the body to store fat and harder to mobilise it.^[3][4] Cortisol, the stress hormone, may become relatively more influential as oestrogen falls, and elevated cortisol is associated with abdominal fat deposition, though the strength of this relationship varies between individuals.^[6][7] Sleep disruption, which is extremely common during menopause due to night sweats and hormonal fluctuation, can further elevate cortisol and disrupt appetite-regulating hormones such as leptin and ghrelin.^[10]

Muscle mass also declines with age, a process called sarcopenia, and this lowers the basal metabolic rate. With fewer calories burned at rest, even an unchanged diet can lead to gradual weight gain. The combination of hormonal change, altered metabolism and disrupted sleep creates conditions that are particularly conducive to visceral fat accumulation, which is why many women notice a change in body shape even when their overall weight has not changed dramatically. The NHS and the British Menopause Society both recognise changes in body composition as a common feature of the menopause transition.

How is visceral fat different from ordinary body fat?

Visceral fat is stored deep within the abdominal cavity, releases inflammatory compounds directly into the liver's circulation, and carries greater risks of type 2 diabetes and cardiovascular disease than subcutaneous fat.

Visceral fat is metabolically active fat stored deep within the abdominal cavity, surrounding organs such as the liver, pancreas and intestines, and it carries greater health risks than subcutaneous fat, which sits just beneath the skin. Subcutaneous fat is the fat you can pinch at the waist or thigh. Visceral fat cannot be felt from the outside, but its presence is associated with increased risk of type 2 diabetes, cardiovascular disease, high blood pressure and certain cancers, in line with NHS and NICE guidance on obesity-related conditions.

The reason visceral fat is more harmful relates to its biological activity. It releases fatty acids, inflammatory cytokines and hormones directly into the portal circulation, which feeds the liver. This contributes to insulin resistance, raised triglycerides and low-grade systemic inflammation. Subcutaneous fat, by contrast, releases its products into the general circulation and has a less direct effect on liver metabolism.

A practical way to estimate visceral fat burden is waist circumference measurement. UK guidance identifies two thresholds for women: a waist circumference above 80 cm is associated with increased cardiometabolic risk, and above 88 cm is associated with very high risk. For women from South Asian, Chinese, Japanese and some other ethnic backgrounds, lower cut-offs apply, and your GP can advise on the most appropriate threshold for you. Waist-to-hip ratio is another useful indicator. Imaging techniques such as MRI or CT scanning can quantify visceral fat precisely, but these are not used routinely in clinical practice. Understanding the distinction between visceral and subcutaneous fat matters because the two respond somewhat differently to intervention, and evidence suggests visceral fat tends to reduce proportionally with overall fat loss in response to aerobic exercise and dietary change.

What diet and lifestyle changes actually reduce visceral fat?

A consistent calorie deficit combined with at least 150 minutes of weekly aerobic exercise and twice-weekly resistance training is the most evidence-supported approach to reducing visceral fat during menopause.

A consistent calorie deficit combined with regular aerobic exercise is the most evidence-supported approach to reducing visceral fat during menopause. Research consistently shows that visceral fat is more metabolically responsive than subcutaneous fat, meaning it tends to reduce proportionally more when overall fat loss occurs. No single food or supplement has been shown to target visceral fat specifically.

Diet principles that support visceral fat reduction include:

• Prioritising protein at each meal to preserve muscle mass and support satiety

• Reducing ultra-processed foods, refined carbohydrates and added sugars, which drive insulin spikes and fat storage

• Including fibre-rich vegetables, legumes and wholegrains to support gut health and blood glucose regulation

• Limiting alcohol, which contributes directly to abdominal fat accumulation and disrupts sleep

• Following a Mediterranean-style dietary pattern, which has good evidence for reducing cardiometabolic risk^[14][15]

Exercise recommendations:

• Aim for at least 150 minutes of moderate-intensity aerobic activity per week, in line with the UK Chief Medical Officers' Physical Activity Guidelines for adults

• Include resistance training at least twice weekly to counteract sarcopenia and maintain metabolic rate

• High-intensity interval training (HIIT) has shown benefit for visceral fat reduction in studies of perimenopausal and postmenopausal women, though the evidence base continues to develop^[18]

Sleep quality and stress management are often overlooked but are clinically relevant. Chronic sleep deprivation and elevated cortisol are both associated with visceral fat deposition.^[6][7] Cognitive behavioural therapy for insomnia (CBT-I) is recommended by NICE as a first-line treatment for insomnia specifically, and addressing insomnia may indirectly support weight management.^[19] If you are experiencing persistent sleep difficulties, speak to your GP. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering weight-management consultations, with prescriber review and pharmacist support, where clinically appropriate options can be discussed.

Can HRT or medication help with menopause-related weight gain?

HRT may reduce menopause-related visceral fat accumulation but is not a weight-loss treatment; GLP-1 medicines such as semaglutide and tirzepatide may support eligible women alongside lifestyle change, subject to prescriber assessment.

Hormone replacement therapy (HRT) does not cause weight loss directly, but evidence suggests it may attenuate the menopause-related shift of fat towards the abdomen by partially restoring oestrogen's influence on fat distribution. Some studies have found that women using HRT accumulate less visceral fat over time compared with those who do not, though HRT is not licensed as a weight-management treatment and should be considered for its broader menopause symptom benefits rather than as a slimming intervention.^[23][24]

HRT is available in various forms including patches, gels, sprays and tablets, and the choice of preparation, oestrogen type and whether a progestogen is needed depends on individual circumstances including whether the uterus is intact. NICE guideline NG23 on menopause recommends that HRT decisions be made on an individual basis, weighing benefits against risks such as venous thromboembolism and breast cancer, which vary by preparation and personal history.^[20][21] Women should discuss HRT with their GP or a menopause specialist.

For women with obesity or significant weight-related health risks, NICE-recommended weight-management medications may be considered alongside lifestyle intervention. GLP-1 receptor agonists such as semaglutide (Wegovy, available in doses up to 2.4 mg weekly for weight management, with a 7.2 mg weekly dose also licensed) and tirzepatide (Mounjaro), which is MHRA-authorised for both type 2 diabetes and chronic weight management, have demonstrated clinically meaningful reductions in body weight in clinical trials.^[26][27] These medicines are not suitable for everyone and require prescriber assessment. They are not a substitute for dietary and lifestyle change but may support it in eligible individuals. NHS access to these medicines depends on NICE technology appraisals and local Integrated Care Board (ICB) commissioning pathways, so eligibility criteria and availability vary; your GP or a specialist service can advise.

Important safety information for GLP-1 medicines: these medicines should not be used during pregnancy or whilst breastfeeding. Women who are planning to conceive should discuss an appropriate washout period with their prescriber before stopping contraception, in line with the relevant SmPC. Women of childbearing potential should note that the Mounjaro UK SmPC advises using an additional non-oral contraceptive method for four weeks after starting and for four weeks after each dose increase, because oral hormonal contraceptives may be affected by delayed gastric emptying.^[29] If you have any concerns about contraception or family planning, speak to your prescriber before starting treatment.

How long does it take to lose visceral fat during menopause?

Measurable reductions in visceral fat typically occur within eight to twelve weeks of consistent lifestyle change, though progress during menopause may be slower than at earlier life stages due to hormonal and metabolic factors.

Meaningful reductions in visceral fat typically become measurable within eight to twelve weeks of consistent lifestyle change, though the timeline varies considerably depending on the degree of calorie deficit, exercise intensity, sleep quality and individual hormonal status. Visceral fat generally responds more quickly than subcutaneous fat to intervention, which means some women notice a reduction in waist circumference before overall body weight changes substantially.

A realistic and sustainable rate of weight loss is generally considered to be 0.5 to 1 kg per week, in line with NHS guidance on healthy weight management. Faster loss is possible in the early weeks, partly due to fluid shifts, but is not necessarily indicative of greater fat loss. Consistency over months rather than weeks is what produces durable change, and the evidence suggests that maintaining muscle mass through resistance training is important for preventing weight regain.

It is worth noting that progress during menopause may be slower than at earlier life stages, partly because of the metabolic changes described above and partly because hormonal fluctuation can affect fluid retention and appetite regulation. This does not mean change is impossible, but it does mean that realistic expectations and patience are important. Women who are not seeing progress despite sustained effort should speak to their GP, who can assess for contributing factors such as thyroid dysfunction, insulin resistance or sleep disorders. If side effects from any prescribed medication are suspected, these should be reported to the prescriber and can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions